Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Equity Ratio (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Equity Ratio for 14 consecutive years, with 0.06 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 138.81% year-over-year to 0.06, compared with a TTM value of 0.06 through Dec 2025, up 138.81%, and an annual FY2025 reading of 0.06, up 138.81% over the prior year.
  • Equity Ratio was 0.06 for Q4 2025 at Heron Therapeutics, down from 0.06 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.63 in Q1 2021 and bottomed at 0.2 in Q2 2023.
  • Average Equity Ratio over 5 years is 0.02, with a median of 0.07 recorded in 2022.
  • The sharpest move saw Equity Ratio crashed 382.32% in 2023, then skyrocketed 138.81% in 2025.
  • Year by year, Equity Ratio stood at 0.25 in 2021, then crashed by 78.69% to 0.05 in 2022, then plummeted by 382.32% to 0.15 in 2023, then rose by 5.47% to 0.14 in 2024, then skyrocketed by 138.81% to 0.06 in 2025.
  • Business Quant data shows Equity Ratio for HRTX at 0.06 in Q4 2025, 0.06 in Q3 2025, and 0.12 in Q2 2025.